BioNTech SE

BioNTech SE

BioNTech SE

Overview
Date Founded

2009

Headquarters

An der Goldgrube 12,Mainz, Rheinland-Pfalz 55131

Type of Company

Public

Employees (Worldwide)

1,310

Industries

Biotechnology
Hospitals & Patient Services
Industrial Machinery & Manufacturing
Retail: Other
Consumer Services
Medical Products & Equipment

Company Description

BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Contact Data
Trying to get in touch with decision makers at BioNTech SE? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder & Chief Executive Officer

Chief Financial Officer & Chief Operating Officer

Chief Business & Commercial Officer

Chief Medical Officer

Chief Strategy Officer & Managing Director

Co-Founder

Vice President Investor Relations & Business Strategy

Vice President, Legal & IP

Supervisory Board

Co-Managing Director at AT Impf GmbH

Professional at Trilantic Capital Management LP

Co-Founder at BioNTech SE

Co-Founder at MIG Verwaltungs AG

Paths to BioNTech SE
Potential Connections via
Relationship Science
You
BioNTech SE
Owners & Shareholders
Details Hidden

Redmill invests in US and non-US healthcare companies. They may also invest in fields related to healthcare where due diligence shows that healthcare assets are the driving force behind value creation and in other sectors from time to time. The firm uses the fundamental research as part of their investment process. Their protocols include company financial models; market models; investment theses; and regular dialogue. Redmill’s sources include contacts with physicians; focus outside US; dialogue with companies; attendance at medical conferences; meetings with private companies; and regular dialogue within the team.

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

Avidity Partners Management LP (APM) is a hedge fund manager headquartered in Dallas, Texas founded by Michael David Gregory. APM provides investment advice.

Recent Transactions
Details Hidden

BioNTech SE issued USD American Depositary Shares

Details Hidden

BioNTech SE purchases BioNTech US, Inc.

Details Hidden

BioNTech SE issued USD American Depositary Shares

Transaction Advisors
Legal Advisor

Advised onBioNTech SE issued USD American Depositary Shares

Underwriter

Advised onBioNTech SE issued USD American Depositary Shares

Underwriter

Advised onBioNTech SE issued USD American Depositary Shares

Managing Director Equities Healthcare

Advised onBioNTech SE issued USD American Depositary Shares

Managing Partner

Advised onBioNTech SE issued USD American Depositary Shares

Legal Advisor

Advised onBioNTech SE issued USD American Depositary Shares

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2019
Market Capitalization
$22.9B
Total Enterprise Value
$6.67B
Earnings Per Share
$-0.95
Revenue
$122M
Net Profit
$-200M
EBITDA
$-167M
EBITDAMargin
-137.81%
Total Debt
$83.3M
Total Equity
$554M
Enterprise Value / Sales
54.85x
TEVNet Income
-33.26x
Debt TEV
0.01x
Investors
Details Hidden

PIML seeks a broad range of investments whose businesses and growth prospects are being inappropriately valued by the market. They employ a team of specialist investment analysts who take a global perspective and apply screening and intensive research to identify investment opportunities. The firm uses a variety of methods to make sense of the universe of stocks available around the world. PIML screens companies in order to be able to build a hypothesis regarding social, political, or economic change. The firm may utilize a multi manager approach in the investment decision making process for providing investment advisory services to funds and client portfolios. Their investment strategies include: adopting a bottom-up stock selection methodology, through which long term capital growth is sought by investing in undervalued securities around the world; seeking absolute returns and not returns relative to any index; investing excess funds in cash when undervalued stocks cannot be found; and actively managing currency.

Details Hidden

HEP seeks invests in fast-growing, market leading companies, operating in China, India, south korea and the ASEAN countries. The firm targets companies operating in the fields of financial services, healthcare, information technology, infrastructure, media, retail, telecommunications, consumer products, logistics and alternative energy. It provides financing for buyout and growth capital requirements with an investment size ranging from $10 to $50 million.

Details Hidden

ATS Beteiligungsverwaltung is an active manager which invests in selected German companies in the biotech sector.

Suppliers
Thermo Fisher Scientific, Inc. Computer Software | Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Genmab A/S Biotechnology | Copenhagen, Denmark

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

4SC AG Pharmaceuticals | Planegg-martinsried, Deu

4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. Its product pipeline includes resminostat and domatinostat. The company was founded by Stefan Busemann, Ulrich Dauer, Klaus-Peter Gulden, and Daniel Vitt in 1997 and is headquartered in Planegg-Martinsried, Germany.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BioNTech SE. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BioNTech SE's profile does not indicate a business or promotional relationship of any kind between RelSci and BioNTech SE.